Skip to main content
. 2020 Oct 12;6(1):101–109. doi: 10.1016/j.ekir.2020.09.046

Figure 3.

Figure 3

Serum proprotein convertase subtilisin kexin 9 (PCSK9) levels before and after treatment with PCSK9 inhibitors. PCSK9 pre, Plasma levels of PCSK9 at the time of diagnosis of nephrotic syndrome and before starting treatment with PCSK9 inhibitors; PCSK9 post, plasma levels of PCSK9 6 months after starting treatment with PCSK9 inhibitors and atorvastatin withdrawal.